338 related articles for article (PubMed ID: 30555037)
1. Novel Antibiotics in the Treatment of Urinary Tract Infections.
Naber KG; Wagenlehner FME
Eur Urol Focus; 2019 Jan; 5(1):10-12. PubMed ID: 30555037
[TBL] [Abstract][Full Text] [Related]
2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
3. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR; Chen WH; Luh KT
Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
[TBL] [Abstract][Full Text] [Related]
4. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
5. [Urosepsis].
Pletz MW; Weis S; Forstner C; Wagenlehner F
Urologe A; 2018 Jan; 57(1):79-92. PubMed ID: 29322236
[TBL] [Abstract][Full Text] [Related]
6. [Urosepsis].
Pletz MW; Weis S; Forstner C; Wagenlehner F
Med Klin Intensivmed Notfmed; 2018 Mar; 113(2):143-156. PubMed ID: 29442147
[TBL] [Abstract][Full Text] [Related]
7. Addressing the challenge of extended-spectrum beta-lactamases.
Zahar JR; Lortholary O; Martin C; Potel G; Plesiat P; Nordmann P
Curr Opin Investig Drugs; 2009 Feb; 10(2):172-80. PubMed ID: 19197795
[TBL] [Abstract][Full Text] [Related]
8. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
[No Abstract] [Full Text] [Related]
9. [Sensitivity to antibiotics of Escherichia coli strains isolated from children admitted to the "Sf. Ioan" clinical emergency hospital for children in Galaţi during 2005-2006].
Florea C
Bacteriol Virusol Parazitol Epidemiol; 2007; 52(1-2):37-44. PubMed ID: 18441957
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of uncomplicated lower urinary tract infections].
Horcajada JP; García-Palomo D; Fariñas MC
Enferm Infecc Microbiol Clin; 2005 Dec; 23 Suppl 4():22-7. PubMed ID: 16854355
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.
Rice LB
Mayo Clin Proc; 2012 Feb; 87(2):198-208. PubMed ID: 22305032
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial drug resistant pathogens in nosocomial urinary tract infections--selected aspects].
Kamińska W; Dzierzanowska D
Pol Arch Med Wewn; 2004 Oct; 112 Spec No():25-32. PubMed ID: 15669199
[TBL] [Abstract][Full Text] [Related]
13. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014.
Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
BMC Infect Dis; 2020 Apr; 20(1):269. PubMed ID: 32264851
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
[TBL] [Abstract][Full Text] [Related]
15. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?
Cooper TW; Pass SE; Brouse SD; Hall RG
Ann Pharmacother; 2011 Feb; 45(2):229-40. PubMed ID: 21304038
[TBL] [Abstract][Full Text] [Related]
16. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?
Rahme C; Butterfield JM; Nicasio AM; Lodise TP
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
[TBL] [Abstract][Full Text] [Related]
18. Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward.
Palwe S; Khobragade K; Kharat AS
Microb Drug Resist; 2020 Jun; 26(6):637-651. PubMed ID: 31851576
[TBL] [Abstract][Full Text] [Related]
19. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008).
Matsumoto T; Hamasuna R; Ishikawa K; Takahashi S; Yasuda M; Hayami H; Tanaka K; Kiyota H; Muratani T; Monden K; Arakawa S; Yamamoto S
Int J Antimicrob Agents; 2011 Mar; 37(3):210-8. PubMed ID: 21242062
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
